Cargando…

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to increase ketone bodies in patients with type 2 diabetes; however, the underlying mechanisms have not been fully elucidated. Here we examined the effect of the SGLT2 inhibitor dapagliflozin (1 mg/kg/day, formulated in a water, PEG40...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallenius, Kristina, Kroon, Tobias, Hagstedt, Therese, Löfgren, Lars, Sörhede-Winzell, Maria, Boucher, Jeremie, Lindén, Daniel, Oakes, Nicholas D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953658/ https://www.ncbi.nlm.nih.gov/pubmed/35120993 http://dx.doi.org/10.1016/j.jlr.2022.100176

Ejemplares similares

Inhibition of SGLT2 Preserves Function and Promotes Proliferation of Human Islets Cells In Vivo in Diabetic Mice
por: Karlsson, Daniel, et al.
Publicado: (2022)

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
por: Pujara, Shreya, et al.
Publicado: (2017)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: Bobrowski, David, et al.
Publicado: (2021)

Disturbed α-Cell Function in Mice with β-Cell Specific Overexpression of Human Islet Amyloid Polypeptide
por: Ahrén, Bo, et al.
Publicado: (2008)

The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
por: Wallenius, Kristina, et al.
Publicado: (2013)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products
por: Xu, Fangfang, et al.
Publicado: (2019)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice
por: Bartesaghi, Stefano, et al.
Publicado: (2022)

Uptake and tissue accretion of orally administered free carboxylic acid as compared to ethyl ester form of docosahexaenoic acid (DHA) in the rat
por: Lindblom, Anna, et al.
Publicado: (2018)

Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists: IDENTIFICATION OF THE STRUCTURAL AND CHEMICAL REQUIREMENTS FOR SELECTIVE ACTIVATION OF FFA2 VERSUS FFA3
por: Schmidt, Johannes, et al.
Publicado: (2011)

LBODP035 When Is Ketosis Just Ketosis?
por: Cannon, Sophie M, et al.
Publicado: (2022)

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors
por: Limenta, Michael, et al.
Publicado: (2019)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Long Chain Fatty Acids as Modulators of Immune Cells Function: Contribution of FFA1 and FFA4 Receptors
por: Hidalgo, Maria A., et al.
Publicado: (2021)

OR23-4 Intestinal FFA2 and FFA3 Mediate Obesogenic Effects in Mice on a Western Diet
por: Gough, Sophie, et al.
Publicado: (2022)

The Role of the Endocrine Glands in Ketosis—I. The Ketosis of Fasting
por: Amatruda, Thomas T., et al.
Publicado: (1959)

Ketosis-Onset Diabetes and Ketosis-Prone Diabetes: Same or Not?
por: Liu, Beiyan, et al.
Publicado: (2013)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

Ketosis in Acute Fevers
por: Hingston, H.
Publicado: (1927)

Control of Fibrinogen Biosynthesis: Role of the FFA/Albumin Ratio
por: Pilgeram, Laurence
Publicado: (2010)

FFA4/GPR120: Pharmacology and Therapeutic Opportunities
por: Milligan, Graeme, et al.
Publicado: (2017)

Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets
por: Ulven, Trond
Publicado: (2012)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
por: Erdogan, Mumin Alper, et al.
Publicado: (2018)

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
por: Ohara, Ken, et al.
Publicado: (2020)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
por: Eldesoqui, Mamdouh, et al.
Publicado: (2022)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
por: Fu, Qianyu, et al.
Publicado: (2023)

FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells
por: Lorza-Gil, Estela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0q47oapotdnup4ri1kne6lhtkm